New pill targets 'Undruggable' cancer mutation in early human trial
NCT ID NCT05002270
Summary
This early-stage study tested a new oral drug, JAB-21822, in adults with advanced solid tumors (like lung or colon cancer) that have a specific genetic change called KRAS G12C. The main goals were to find a safe dose and see if the drug, given alone or with another cancer drug (cetuximab), could shrink tumors. It involved 29 people whose cancer had progressed after at least one prior standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinc
Phoenix, Arizona, 85054, United States
-
Mayo Clinc
Scottsdale, Arizona, 85259, United States
-
Mayo Clinc
Jacksonville, Florida, 32224, United States
-
University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.